Despite effective antibiotics, Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis, still infects nearly one-third of the world's population. While key immune factors including CD4+ T cells and IFNg production have been identified, there are still many antimicrobial mechanisms yet to be explored. Here we characterized the role of invariant natural killer T (iNKT) cells and GM-CSF during Mtb infection.

This work presents an all-Mach method for two-phase inviscid flow in the presence of surface tension. A modified version of the Hartens, Lax, Leer and Contact (HLLC) approximate Riemann solver based on Garrick et al. [1] is developed and combined with the popular Volume of Fluid (VoF) method: Compressive Interface Capturing Scheme for Arbitrary Meshes (CICSAM). This novel combination yields a scheme with both HLLC shock capturing as well as accurate liquid-gas interface tracking characteristics. To ensure compatibility with VoF, the Monotone Upstream-centred Scheme for Conservation Laws (MUSCL) [2] is applied to non-conservative (primitive) variables, which yields both robustness and accuracy. Liquid-gas interface curvature is computed via both height functions [3, 4] and the convolution method [5]. This is in the interest of applicability to both cartesian and arbitrary meshes. The author emphasizes the use of VoF in the interest of surface tension modelling accuracy. The method is validated using a range of test-cases available in literature. The results show flow features that are in agreement with experimental and benchmark data. In particular, the use of the HLLC-VoF combination leads to a sharp volume fraction and energy field with improved accuracy (up to secondorder).

A patient presented with severe bactrim-induced neutropenia with a reversed CD4+/CD8+ lymphocyte ratio. R-metHUG-CSF at 300 μg daily produced a dramatic neutrophil response and the therapy was discontinued after 2 weeks.

Indiana University-Purdue University Indianapolis (IUPUI) / Hydrocephalus is a disease characterized by an increase in cerebrospinal fluid (CSF) in the ventricles of the brain. This manifests as a result of either overproduction or underabsorption of CSF leading to increases in pressure, swelling and loss of brain matter. Current treatments for this disease include surgical interventions via the introduction of shunts or endoscopic third ventriculostomy, both of which aim to redirect flow of CSF in to another cavity for absorption. Limited pharmacotherapies are available in the treatment of hydrocephalus, and there exists a clinical need for drug therapies, which can ameliorate the pathophysiology associated with hydrocephalus and ventriculomegaly. CSF is produced primarily by the choroid plexus (CP), found in the ventricles of the brain. Composed of a high resistance epithelium surrounding a capillary network, the CP epithelium acts as a barrier, regulating ion transport between the CSF and blood. Transient Receptor Potential Vanilloid-4 (TRPV4) is a nonselective Ca2+-permeable cation channel expressed in the CP which is being investigated for its role in CSF production. To study hydrocephalus, we utilize two model systems; the TMEM67-/- Wpk rat, and the PCP-R cell line. The Wpk rat model is used to study the effects of drug intervention on the development and progression of hydrocephalus. The PCP-R cell line is utilized for studies which aim to understand the mechanisms by which CSF is produced. Using Ussing chamber electrophysiology, we are able to study the role of specific channels, transporters and modulators in driving epithelial ion flux across the CP. This research aims to establish a role for TRPV4 in production and regulation of CSF, and to interrogate a mechanism by which this ion transport occurs. The chapters that follow describe components of the pathway by which TRPV4 is activated and ion flux is stimulated.

No description available.

No description available.

No description available.

No description available.

L’allogreffe de cellules souches hématopoïétiques (CSH) reste à l’heure actuelle la seule thérapie curative de nombreuses hémopathies malignes. Les lymphocytes T (LT) du donneur constituent une immunothérapie contre les cellules de la leucémie (ou lymphome) appelé effet « GVL » pour « Graft versus Leukemia ». Malheureusement cet effet est intimement lié à la maladie du greffon contre l’hôte appelée « GVH » pour « Graft versus Host » (destruction des cellules saines du receveur par les LT du donneur). L’allogreffe de CSH est de plus en plus souvent réalisées avec des greffons mobilisés par du G-CSF. Quelques publications identifient des cellules immunosuppressives avec un phénotype peu précis CD11b+ Gr1+ induites par le G-CSF pouvant regrouper plusieurs sous-types cellulaires et sans trouver de contre-partie humaine ou avec un mécanisme d’action peu clair. Nous avons démontré que le G-CSF mobilise chez l’homme, dans la fraction CD34+ du greffon, une population monocytaire. Lorsqu’elle représente plus de 12% des CD34+, les receveurs ont une incidence moindre de la GVH aiguë. Cette même population est phénotypiquement et fonctionnellement conservée chez la souris. En réponse à l’IFN-γ relargué par les LT allogéniques, elle produit de l’Oxyde Nitrique capable d’induire l’apoptose de ces LT in vitro. In vivo, nous avons pu décortiquer (chez la souris uniquement) les mécanismes de régulation de la GVH aiguë. Les LT apoptotiques phagocytés par les macrophages capables alors de devenir tolérogènes en produisant du TGF-β et ainsi d’induire des LT régulateurs. Dans le modèle murin d’allogreffe de CSH, le transfert adoptif de cette population purifiée protège le receveur de la GVH aiguë. Nous pensons que si cette population peut être cultivée et expandue ex vivo, elle pourrait être une thérapie cellulaire préventive contre la GVH. / Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) is the most effective immunotherapy for acute leukemia, due to the development of graft-versus-leukemia (GVL) effect mediated by alloreactive donor T cells. However, donor T cells specific for recipient alloantigens are also responsible for graft-versus-host disease (GVHD), a life-threatening complication that frequently occurs after allo-HSCT. The administration of Granulocyte colony stimulating factor (G-CSF) is routinely performed to collect Peripheral Blood Stem Cells (PBSC) from healthy donors for allo-HSCT. Few studies identified that G-CSF can induce myeloid suppressive cells in mice (CD11b+ Gr1+) with no human counterpart. We demonstrated in our study that G-CSF can induce a new population named CD34+Monocyte. The cumulative incidence of acute grade II to IV GVHD following allo-HSCT was lower in patients receiving grafts containing CD34+ monocyte frequencies above 12% of the CD34+ population. In mice, we demonstrated that G-CSF mobilized a highly conserved CD34+ monocyte population. CD34+Monocytes require T cell-mediated IFN-γ to produce Nitric Oxide that inhibits T cell activation and proliferation. In vivo, we report that CD34+ monocyte-derived NO regulates the alloreactive response by inducing T cell apoptosis and subsequently, the induction of regulatory T cells. In fact, uptake of apoptotic T cells by macrophages triggers them to produce high levels of TGF-β that drives the expansion of Tregs and induces immune tolerance. Such tolerogenic monocytes could represent a good candidate for the development of novel immunoregulatory and therapeutic cellular therapies.

Colony-stimulating factor 1 receptor (CSF1R, Fms) is an integral transmembrane glycoprotein with tyrosine specific protein kinase activity that it is found on the mononuclear phagocytes to promote their survival, proliferation and differentiation. Colony-stimulating factor 1 (CSF-1), also known as M-CSF, is a protein ligand that acts on the CSF1R. There is a variable association of Fms with the stem cell marker CD34 on acute myeloid leukemia (AML) cells and this suggests different structures of the AML hierarchy in different patients. Mouse stromal cells (MS-5) were transduced with a plasmid containing human CSF-1 because mouse CSF-1 is inactive on human CSF1R. Results show that AML cells cultured with CSF-1-expressing stroma had a much better growth and survival than the control stroma, suggesting that CSF-1 might be a stimulating factor for the growth of leukemic stem cells.